Parathyroid Hormone and Bone Building

Bone Peptides

65%

Reduction in vertebral fracture risk in postmenopausal women receiving daily teriparatide (PTH 1-34) injections for a median of 21 months in the landmark Neer et al. trial.

Neer et al., New England Journal of Medicine, 2001

Neer et al., New England Journal of Medicine, 2001

View as image

Parathyroid hormone is a peptide that dissolves bone. It activates osteoclasts, the cells that break down mineralized tissue, to release calcium into the bloodstream. In hyperparathyroidism, where PTH levels are chronically elevated, patients lose bone density and develop fractures. Yet the same hormone, given as a daily injection, is one of the most effective bone-building drugs ever developed. Teriparatide (Forteo), a synthetic version of the first 34 amino acids of PTH, reduced vertebral fractures by 65% and nonvertebral fractures by 53% in postmenopausal women in its pivotal 2001 trial.^[1] This paradox, a bone-destroying hormone that builds bone, is not a marketing trick. It is a fundamental property of how the PTH receptor translates signal duration into opposing biological outcomes. Understanding this mechanism matters for anyone reading about peptide-based osteoporosis treatments. For an overview of how PTH-based drugs compare head-to-head, see the dedicated comparison article. For the newer analog, see the pillar article on abaloparatide.

The PTH Paradox: Duration Determines Direction

PTH is produced by four small glands behind the thyroid. Its primary job is calcium homeostasis: when blood calcium drops, PTH is secreted and acts on bone, kidneys, and intestines to restore calcium levels. In bone, this means activating osteoclasts to release stored calcium from the mineralized matrix.

In primary hyperparathyroidism, where a parathyroid adenoma secretes PTH continuously, patients develop osteopenia and osteoporosis. Cortical bone is particularly affected, with thinning of the long bones and increased fracture risk. The hormone, in this context, is unambiguously catabolic.

The paradox was first recognized in the 1970s and 1980s, when researchers discovered that intermittent injection of PTH in animals produced the opposite effect: increased bone formation, greater trabecular thickness, and higher bone mineral density. Podbesek and colleagues (1983) showed that daily PTH injections in rats increased trabecular bone volume by 40-60% over 4 weeks, while continuous infusion of the same total daily dose caused bone loss.

The explanation lies in how the PTH1 receptor (PTH1R) translates signal duration into different intracellular cascades.

Receptor Signaling: Two Pathways, Two Outcomes

PTH1R is a G protein-coupled receptor expressed on osteoblasts (bone-forming cells) and osteocytes (mature bone cells embedded in mineralized tissue). When PTH binds, it activates two major signaling pathways:

The cAMP/PKA pathway is activated rapidly by brief PTH exposure. This pathway promotes osteoblast differentiation and proliferation, increases the expression of bone formation genes (including Runx2 and osterix), and suppresses osteoblast apoptosis. Crucially, transient cAMP signaling also suppresses sclerostin (encoded by the SOST gene) in osteocytes.^[2] Sclerostin is a potent inhibitor of the Wnt signaling pathway, which is the master regulator of bone formation. When PTH suppresses sclerostin, Wnt signaling is de-repressed, and osteoblasts receive a powerful "build bone" signal.

The RANKL/OPG axis is activated by sustained PTH exposure. Osteoblasts and osteocytes respond to prolonged PTH stimulation by increasing production of RANKL (receptor activator of nuclear factor kappa-B ligand), the key cytokine that recruits and activates osteoclasts. Simultaneously, they decrease production of OPG (osteoprotegerin), the decoy receptor that normally blocks RANKL. The shift in the RANKL/OPG ratio favors osteoclast activity and bone resorption.

With intermittent dosing, the brief pulse of PTH activates the anabolic cAMP pathway and suppresses sclerostin before the RANKL/OPG shift can produce significant resorption. The hormone is cleared within hours, and during the 23-hour gap until the next injection, osteoblasts respond to the Wnt signal by building new bone. With continuous exposure, the RANKL pathway stays active, osteoclasts remain recruited, and resorption dominates.

This is not unique to PTH. Several signaling systems in biology produce opposite effects depending on signal duration, a phenomenon called "temporal encoding." PTH is simply the most clinically consequential example in peptide pharmacology.

The Anabolic Window

When patients begin daily teriparatide injections, bone formation markers (P1NP, osteocalcin) rise within weeks. Bone resorption markers (CTX, NTX) also rise, but with a delay of 3-6 months. This creates an "anabolic window" during the first 6-12 months of treatment when formation outpaces resorption, producing net bone gain.

Potts (2005) described this phenomenon in his review of PTH physiology and pharmacology, noting that the early formation response without resorption represents a true modeling effect (new bone laid down on surfaces that were previously quiescent), while the later increase in resorption represents a remodeling effect (coupled bone turnover).^[3]

After approximately 18-24 months, the anabolic window closes as resorption catches up. Net bone gain plateaus, which is one reason treatment is typically limited to 2 years. The other reason is a precautionary signal from animal studies.

The Osteosarcoma Question

In the pre-clinical testing of teriparatide, Fisher 344 rats receiving high doses (3-75 times the human dose) for nearly their entire lifespan (2 years) developed osteosarcoma (bone cancer) at elevated rates. This finding led the FDA to issue a black box warning when teriparatide was approved in 2002 and to limit treatment duration to 2 years.

Twenty years of post-marketing surveillance have not confirmed this risk in humans. The Forteo Patient Registry, which tracked over 130,000 teriparatide-treated patients, found no increased rate of osteosarcoma compared to the general population. Osteosarcoma in rats is far more common than in humans (rats develop spontaneous bone tumors at high baseline rates), and the doses used in the animal studies were far above therapeutic levels. In 2020, the FDA removed the black box warning, though the 2-year treatment limit remains in the prescribing information.

This history is relevant because the osteosarcoma concern delayed broader adoption of teriparatide and drove the development of abaloparatide, a PTHrP analog designed to have a more transient receptor interaction and potentially lower bone resorption activation.

Clinical Evidence: The Neer Trial and Beyond

The Fracture Prevention Trial (2001)

The pivotal trial by Neer and colleagues randomized 1,637 postmenopausal women with prior vertebral fractures to teriparatide 20 mcg/day, teriparatide 40 mcg/day, or placebo for a median of 21 months.^[1]

Results at the 20 mcg dose (the approved dose):

• 65% reduction in new vertebral fractures (RR 0.35, 95% CI 0.22-0.55)
• 53% reduction in nonvertebral fragility fractures (RR 0.47, 95% CI 0.25-0.88)
• Lumbar spine BMD increased by 9.7%
• Femoral neck BMD increased by 2.8%

The trial was stopped early because of the osteosarcoma finding in rats, not because of any safety signal in humans. The results established teriparatide as the first anabolic bone agent, a class distinct from antiresorptive drugs (bisphosphonates, denosumab) that slow bone loss but do not build new bone. For a detailed look at the clinical pharmacology and practical use of this drug, see Teriparatide (Forteo): The Parathyroid Hormone Peptide That Builds Bone.

The Quality of PTH-Built Bone

A question that initially concerned researchers was whether the bone built by teriparatide was structurally sound or artificially inflated in density without proportional strength. Bone biopsy studies from teriparatide trials addressed this directly. Jiang and colleagues (2003) examined iliac crest biopsies from women in the Neer trial and found that teriparatide increased trabecular thickness, improved trabecular connectivity, and enhanced cortical thickness at the cellular level, all without evidence of woven bone (disordered, mechanically weak bone) or marrow fibrosis.

Microarchitectural analyses using micro-CT confirmed that teriparatide-built bone has normal lamellar structure and appropriate mineralization. This distinguishes anabolic agents from fluoride, an earlier bone-building drug that increased bone density on DXA but produced brittle, structurally inferior bone and actually increased fracture rates. The PTH-built bone is genuinely stronger, not just denser on a scan.

Who Benefits Most

Teriparatide is most effective in patients with severe osteoporosis: those with multiple prior fractures, very low BMD (T-score below -3.5), or failure of antiresorptive therapy. In the VERO trial, teriparatide was directly compared to risedronate (a bisphosphonate) as first-line treatment in high-risk patients and proved superior, with 56% fewer vertebral fractures.^[4] This was the first trial to show superiority of one osteoporosis drug over another in fracture reduction, not just BMD improvement.

Patients who have been on long-term bisphosphonate therapy may have a blunted response to teriparatide, as bisphosphonates suppress the bone remodeling machinery that PTH requires to exert its anabolic effect. The sequence matters: starting with teriparatide and following with a bisphosphonate or denosumab produces better outcomes than the reverse order.

Sequential Therapy

A critical clinical lesson emerged after the initial trials: stopping teriparatide without follow-up antiresorptive therapy leads to rapid bone loss. The bone gained during teriparatide treatment is new, relatively undermineralized trabecular bone that is vulnerable to resorption once the anabolic signal is removed.

Current guidelines recommend transitioning to a bisphosphonate or denosumab after completing teriparatide treatment. The VERO trial (Kendler et al., 2018) compared teriparatide followed by denosumab versus risedronate alone and found that the sequential approach produced significantly greater gains in BMD and a 56% lower rate of new vertebral fractures.^[4]

PTH vs. PTHrP Analogs

Chen and colleagues (2021) reviewed the differences between PTH and PTH-related protein (PTHrP) signaling at the PTH1 receptor. PTHrP, the natural ligand that shares the receptor with PTH, produces more transient receptor activation and appears to favor formation over resorption even more cleanly than PTH.^[5] This insight led to the development of abaloparatide, a synthetic PTHrP analog approved in 2017 that may produce a wider anabolic window with less hypercalcemia than teriparatide.

PTH in Context: Why It Matters for Peptide Science

The PTH story illustrates several principles relevant across peptide pharmacology:

Signal duration matters as much as signal strength. The same receptor, activated by the same peptide, produces opposite effects depending on exposure pattern. This principle applies broadly: GLP-1 receptor agonists use lipid acylation to extend their half-life, which produces sustained signaling distinct from the pulsatile pattern of endogenous GLP-1.

Peptide drugs can do what small molecules cannot. No small molecule mimics the anabolic action of PTH on bone. The specificity of the PTH-PTH1R interaction, including the peptide's ability to stabilize different receptor conformations depending on binding kinetics, is a property of the large binding interface that peptides provide.

The anabolic window concept applies beyond bone. In growth hormone physiology, pulsatile GH release produces different metabolic effects than continuous exposure. In calcitonin pharmacology, the timing and pattern of receptor activation similarly determines whether the net effect is protective or leads to receptor desensitization. The connection between bone health and weight loss drugs is explored in the article on GLP-1s and bone density.

Limitations and Ongoing Questions

The 2-year treatment limit remains a practical constraint, even though the osteosarcoma risk appears to be rat-specific. Some clinicians advocate for longer treatment in patients with severe osteoporosis, but no trial has tested teriparatide beyond 2 years.

Cost is a significant barrier. Teriparatide costs approximately $3,000-4,000 per month in the United States without insurance coverage. Biosimilar versions have entered the market in some countries, potentially improving access.

The mechanism of the anabolic window closing is not fully understood. Whether the plateau in bone formation after 18-24 months reflects osteoblast exhaustion, sclerostin rebound, or some other adaptive response is an active area of investigation. Chang and colleagues (2025) used transcriptomic analysis to characterize the metabolic changes in osteocytes during chronic PTH exposure, identifying potential targets to extend the anabolic window.^[6]

Not all bone responds equally. PTH preferentially stimulates trabecular bone (spine, hip) over cortical bone (long bones). In fact, cortical bone may initially thin during teriparatide treatment due to increased cortical porosity, even as overall bone strength improves through trabecular thickening. This creates a paradox where DXA scans at cortical sites may underestimate the true strength gains.

The Bottom Line

Parathyroid hormone builds bone when given intermittently and destroys it when present continuously. The difference comes down to receptor signaling kinetics: brief PTH exposure activates cAMP/PKA signaling and suppresses sclerostin, enabling Wnt-driven bone formation. Sustained exposure shifts the RANKL/OPG ratio toward osteoclast activation and bone resorption. Teriparatide, the synthetic PTH 1-34 fragment, reduced vertebral fractures by 65% in its landmark trial and remains the reference standard for anabolic osteoporosis treatment. Current limitations include the 2-year treatment cap, high cost, and the need for follow-up antiresorptive therapy to maintain gains. The PTHrP analog abaloparatide was designed to exploit the same receptor with a more transient activation pattern.

Frequently Asked Questions

How does parathyroid hormone build bone?

When given as a brief daily injection, PTH activates the cAMP/PKA pathway in osteoblasts and suppresses sclerostin in osteocytes. Sclerostin normally blocks Wnt signaling, the master pathway for bone formation. With sclerostin suppressed, osteoblasts receive a strong signal to build new bone. This anabolic effect occurs during the first hours after injection; by the time the next dose arrives 24 hours later, osteoblasts have been stimulated without sustained osteoclast activation.

Why does continuous PTH cause bone loss?

Sustained PTH exposure increases the RANKL/OPG ratio in osteoblasts and osteocytes, which recruits and activates osteoclasts, the cells that break down bone. This is what happens in hyperparathyroidism, where a parathyroid adenoma continuously secretes PTH. The resorption pathway dominates over formation, leading to net bone loss, particularly in cortical bone.

How effective is teriparatide for osteoporosis?

In the landmark Neer et al. (2001) trial of 1,637 postmenopausal women, daily teriparatide (20 mcg) reduced vertebral fractures by 65% and nonvertebral fractures by 53% over a median of 21 months. Lumbar spine BMD increased by 9.7%. It is the reference standard for anabolic osteoporosis treatment and is most effective when followed by an antiresorptive drug like denosumab.

Does teriparatide cause bone cancer?

In rats given high doses (3-75x human dose) for their entire lifespan, osteosarcoma rates increased. Over 20 years of human surveillance, including a registry of 130,000+ patients, no increased osteosarcoma risk has been detected. The FDA removed the black box warning in 2020. Treatment is still limited to 2 years as a precaution, though the rat finding appears species-specific.

What is the anabolic window for PTH?

The anabolic window is the first 6-12 months of teriparatide treatment when bone formation markers rise before resorption markers catch up. During this period, the net effect is pure bone gain. After 18-24 months, resorption increases to match formation, and net bone gain plateaus. This is one reason treatment is limited to 2 years.

What is the difference between teriparatide and abaloparatide?

Teriparatide is a synthetic form of PTH (amino acids 1-34). Abaloparatide is a synthetic analog of PTH-related protein (PTHrP), which shares the same receptor but produces more transient activation. In clinical trials, abaloparatide produced similar bone density gains with less hypercalcemia. Both are approved for osteoporosis. For a detailed comparison, see the dedicated article.